PPI Versus Histamine Antagnists as Adjuvant to Chemotherapy
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: CHOP, CHOP Plus Lanzoprazole, CHOP Plus Famotidine.
- Who it may be relevant to
- Registry conditions: Lymphoma. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Comparative Clinical and Biochemical Study Evaluating the Effect of Proton Pump I Nhibitors Versus Histamine 2 Receptor Antagonists as an Adjuvant With Chemotherapy in Patients With Non-hodgkin Lymphoma.
Overview
The study is a Comparative Clinical and Biochemical Study Evaluating the effect of Proton Pump I nhibitors versus histamine 2 Receptor antagonists as an adjuvant with chemotherapy in patients with Non-hodgkin Lymphoma.
Detailed description
The study is a Comparative Clinical and Biochemical Study Evaluating the effect of Proton Pump Inhibitors versus histamine 2 Receptor antagonists as an adjuvant with chemotherapy in patients with Non-hodgkin Lymphoma to compare the difference in efficacy.
Interventions
- Drug CHOP
CHOP only - Drug CHOP Plus Lanzoprazole
CHOP plus Lanzoprazole 60 mg - Drug CHOP Plus Famotidine
CHOP Plus Famotidine 40 mg
Primary outcome measures
- Number of patients eith radiological and clinical improvement [Time frame: 6 months]
Eligibility criteria
Inclusion criteria
- DLBCL Lymphoma subtype --No comorbid disease
Exclusion criteria
- Pregnancy
- Peptic ulcer
- Severe cardiac disease
- Osteoporosis
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Egypt · 1 center
- Sherief Abd-Elsalam — Cairo
Publications
- Hegazy SK, El-Haggar SM, Alhassanin SA, El-Berri EI. Comparative randomized trial evaluating the effect of proton pump inhibitor versus histamine 2 receptor antagonist as an adjuvant therapy in diffuse large B-cell lymphoma. Med Oncol. 2021 Jan 4;38(1):4. doi: 10.1007/s12032-020-01452-z. PMID 33394214
Identifiers
NCT: NCT03647072 · eman elberry